Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $92
Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $92
Barrington Research維持勒梅特微管醫療股票的跑贏市場評級，將其價格目標上調至92美元。
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $79 to $92.
Barrington Research分析師Michael Petusky維持對勒梅特微管醫療(NASDAQ:LMAT)的強力推薦並將目標股價從79美元上調至92美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。